Syndax Pharmaceuticals Inc.

231 articles with Syndax Pharmaceuticals Inc.

• Syndax Pharmaceuticals Announces Two Publications in Nature of Data from the Phase 1 Portion of AUGMENT-101 in Acute Leukemia Patients

  3/15/2023

  Syndax Pharmaceuticals, Inc. (Nasdaq: SNDX) today announced that data from the Phase 1 portion of the ongoing Phase 1/2 AUGMENT-101 trial of revumenib in patients with nucleophosmin mutant (mNPM1) and KMT2A-rearranged (KMT2Ar) relapsed/refractory (R/R) acute leukemia and an analysis describing MEN1 mutations observed in the study have been published in the journal Nature.

• Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

  3/6/2023

  Syndax Pharmaceuticals, Inc.  today announced that on March 1, 2023 the Company granted an inducement award to purchase up to 15,200 shares of common stock to one new employee under the Company's 2023 Inducement Plan.

• Syndax Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Clinical and Business Update

  2/28/2023

  Syndax Pharmaceuticals, Inc. (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today reported its financial results for the fourth quarter and full year ended December 31, 2022 and provided a business update.

• Syndax to Announce Fourth Quarter and Year-end 2022 Financial Results and Host Conference Call and Webcast on February 28, 2023

  2/21/2023

  Syndax Pharmaceuticals, Inc. today announced that it will report its fourth quarter and year-end 2022 financial results and provide a business update on Tuesday, February 28, after the close of the U.S. financial markets.

• Syndax Announces Participation at Upcoming Investor Conferences - February 14, 2023

  2/14/2023

  Syndax Pharmaceuticals, Inc. announced that members of its management team will participate in the upcoming investor conferences.

• Syndax Announces Presentation at 41st Annual J.P. Morgan Healthcare Conference

  1/4/2023

  Syndax Pharmaceuticals, Inc. announced that Michael A. Metzger, Chief Executive Officer of Syndax, will present at the 41st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2023 at 10:30 a.m. PT/ 1:30 p.m. ET.

• Syndax Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares

  12/14/2022

  Syndax Pharmaceuticals, Inc. announced the closing of its previously announced underwritten public offering of 7,840,909 shares of its common stock at a price to the public of $22.00 per share.

• Syndax Announces Positive Updated Data from Phase 1 Portion of AUGMENT-101 Trial of Revumenib in Patients with Acute Leukemias During Oral Presentations at 64th ASH Annual Meeting

  12/10/2022

  Syndax Pharmaceuticals, Inc. presented updated positive data from the Phase 1 portion of the ongoing Phase 1/2 AUGMENT-101 trial of revumenib in patients with nucleophosmin mutant and KMT2A rearranged relapsed/refractory acute myeloid or acute lymphoid leukemias.

• Syndax Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) - December 08, 2022

  12/8/2022

  Syndax Pharmaceuticals, Inc. announced that in connection with the hiring, announced on December 5, 2022, of Steve M. Sabus as Chief Commercial Officer, Mr. Sabus received an inducement award to purchase up to 220,000 shares of common stock.

• Syndax Announces Pricing of $150 Million Public Offering of Common Stock - December 07, 2022

  12/7/2022

  Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, announced the pricing of an underwritten public offering of 6,818,182 shares of its common stock.

• Syndax Announces Proposed $150 million Public Offering of Common Stock - December 06, 2022

  12/6/2022

  Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, announced that it plans to offer and sell, subject to market and other conditions, $150 million of shares of its common stock in an underwritten public offering.

• Syndax Announces U.S. FDA Breakthrough Therapy Designation Granted for Revumenib for the Treatment of Adult and Pediatric Patients with Relapsed or Refractory KMT2A- Rearranged (MLLr) Acute Leukemia

  12/5/2022

  Syndax Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) for revumenib for the treatment of adult and pediatric patients with relapsed or refractory (R/R) acute leukemia harboring a KMT2A rearrangement (KMT2Ar).

• Syndax Pharmaceuticals and Incyte Announce Axatilimab Phase 1/2 Data in Patients with Chronic Graft-Versus-Host Disease Published in the Journal of Clinical Oncology

  12/5/2022

  Syndax Pharmaceuticals, Inc. (Nasdaq: SNDX) and Incyte (Nasdaq: INCY) today announced that  results from the Phase 1/2 trial of axatilimab, Syndax's anti-CSF-1R antibody, in patients with recurrent or refractory chronic graft-versus-host disease (cGVHD) following two or more prior lines of therapy, were published in the Journal of Clinical Oncology.

• Syndax Pharmaceuticals Announces Appointment of Steve Sabus as Chief Commercial Officer

  12/2/2022

  Syndax Pharmaceuticals, Inc. today announced the appointment of Steve Sabus to the role of Chief Commercial Officer, effective December 5 , 2022.

• Syndax Announces Participation at Evercore ISI Annual HealthCONx Conference

  11/21/2022

  Syndax Pharmaceuticals, Inc. today announced that members of its management team will participate in a fireside chat at the Evercore ISI Annual HealthCONx Conference on Wednesday, November 30, 2022, at 3:30 p.m.

• Syndax Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Clinical and Business Update

  11/3/2022

  Syndax Pharmaceuticals, Inc. (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today reported its financial results and provided a business update for the third quarter ended September 30, 2022.

• Syndax Announces Positive Updates to Clinical Activity and Durable Remissions in Phase 1 Portion of AUGMENT-101 Trial of Revumenib in Patients with Acute Leukemias

  11/3/2022

  Syndax Pharmaceuticals, Inc. (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced updated positive data from the Phase 1 portion of the ongoing Phase 1/2 AUGMENT-101 trial of revumenib in patients with nucleophosmin (NPM1) mutant and mixed lineage leukemia rearranged (MLLr) relapsed/refractory (R/R) acute leukemias.

• Syndax to Announce Third Quarter 2022 Financial Results and Host Conference Call and Webcast on November 3, 2022

  10/27/2022

  Syndax Pharmaceuticals, Inc. announced that it will report its third quarter 2022 financial results and provide a business update on Thursday, November 3, after the close of the U.S. financial markets.

• Syndax Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Clinical and Business Update

  8/8/2022

  Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today reported its financial results and provided a business update for the second quarter ended June 30, 2022.

• Syndax to Announce Second Quarter 2022 Financial Results and Host Conference Call and Webcast on August 8, 2022

  8/2/2022

  Syndax Pharmaceuticals, Inc. (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that it will report its second quarter 2022 financial results on Monday, August 8, after the close of the U.S. financial markets.